Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Oculis Holding AG OCS

Healthcare
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody... see more

Recent & Breaking News (NDAQ:OCS)

Oculis to Present at the Stifel 2024 Healthcare Conference

GlobeNewswire November 13, 2024

Oculis Reports Q3 2024 Financial Results and Provides Company Updates

GlobeNewswire November 7, 2024

Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees

GlobeNewswire October 21, 2024

Oculis' DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024

GlobeNewswire October 15, 2024

Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer

GlobeNewswire October 2, 2024

Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award

GlobeNewswire September 19, 2024

Oculis to Present at Upcoming September Investor Conferences

GlobeNewswire August 29, 2024

Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update

GlobeNewswire August 27, 2024

Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer

GlobeNewswire August 15, 2024

Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

GlobeNewswire July 30, 2024

Oculis and EURETINA Announces the Ramin Tadayoni Award

GlobeNewswire June 27, 2024

Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy

GlobeNewswire June 10, 2024

Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

GlobeNewswire May 30, 2024

Oculis Reports Q1 2024 Financial Results and Provides Company Updates

GlobeNewswire May 8, 2024

Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis

GlobeNewswire May 8, 2024

Oculis to Present at Bank of America Global Healthcare Conference

GlobeNewswire May 6, 2024

Oculis Publishes Invitation to the Annual General Meeting

GlobeNewswire April 29, 2024

Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market

GlobeNewswire April 22, 2024

Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market

GlobeNewswire April 11, 2024

Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development

GlobeNewswire April 10, 2024